Tanabe Pharma announced positive Phase 3 data for an oral drug targeting two rare diseases, marking its first major clinical milestone since Bain Capital acquired the company. The update advances the program toward potential regulatory discussions, adding momentum to a pipeline focused on rare conditions with limited treatment options.